Assessment of Calcium and Vitamin D Medications Adherence in Patients with Hypoparathyroidism After Thyroidectomy

Muhammet Cuneyt Bilginer (✉ cuneytbilginer@hotmail.com)  
Karadeniz Teknik Üniversitesi Tıp Fakültesi  https://orcid.org/0000-0002-7652-7648

Cevdet Aydin  
Yıldırım Beyazıt University Faculty of Medicine: Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi

Burçak Polat  
Yıldırım Beyazıt University Faculty of Medicine: Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi

Sevgül Faki  
Ankara City Hospital: Ankara Sehir Hastanesi

Oya Topaloglu  
Yıldırım Beyazıt University Faculty of Medicine: Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi

Reyhan Ersoy  
Yıldırım Beyazıt University Faculty of Medicine: Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi

Bekir Çakır  
Yıldırım Beyazıt University Faculty of Medicine: Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi

Research Article

Keywords: Hypoparathyroidism, Calcium, Vitamin D, Medications adherence, Patient compliance

Posted Date: November 3rd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1019403/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Endocrine Abstracts on May 8th, 2018. See the published version at https://doi.org/10.1530/endoabs.56.P231.
Abstract

Summary: In this study, we found that patients with hypoparathyroidism had a problem with calcium medication compliance, and this problem increased with the duration of the disease. We also showed that patients are concerned about the possible side effects of drugs.

Introduction: In this study, we aimed to evaluate adherence to avtive vitamin D and calcium replacement in patients with post surgical hypoparathyroidism.

Methods: To elucidate the medication adherence, we performed a questionnaire survey using the six item “Medication adherence questionnaire”(MAQ). The first, second and sixth questions reflect the motivation status of the patients whereas the third, forth and sixth questions reflect the knowledge about the medication that is received. The responses are scored and patients are classified regarding their motivation to and knowledge about the particular drug.

Results: Totally 64 patients (Male:12/Female:52; mean age 48.6±11.6 years) who had postoperative hypoparathyroidism were included in our study. Median disease durance was 60 months (min-max; 12-295 months). We found that motivation score of calcium usage was signicantly lower compared to vitamin D usage (p<0.001). The calcium motivation score was reversely correlated with disease duration (r= -0.256 and p=0.046). The most common worry about calcium usage was nephrotoxicity, and the most common worries about calcitriol treatment were kidney damage and polyuria. One third of the patients were taking oral calcium and calcitriol less than the recommended dose.

Conclusion: One third of patients lack motivation to use calcium whereas half of the patients’ experiences anxiety about drug related side effects. This is a preliminary study showing that vital calcium and active vitamin D intake may be interrupted due to side effect anxiety and motivation can be increased by frequent visits and acknowledging the patient about the deleterious effects of drug withdrawal.

Introduction

Hypoparathyroidism (HypoPT) is defined as dysfunctional production and/or secretion of parathormone (PTH) by the parathyroid glands. It is characterized with hypocalcemia and hyperphosphatemia. The most common etioloogy is surgical removal of the parathyroid glands during thyroidectomy or other neck operations. After total thyroidectomy, the incidence of post-operative HypoPT ranges from 0.5–6.6% [1]. However, incidences as high as 20% have been reported depending on surgery extension and complexity. HypoPT is called as “persistent” or “chronic” if it lasts longer than 6 months to one year [2, 3]. All patients should be treated if their serum Calcium (Ca) is lower than 8 mg/dl [4, 5]. While treating the patients with hypoPT there are 6 applied principles used for monitoring. Those are as follows; 1) serum Ca should be slightly below normal 2) there should be no sign or symptom of hypocalcemia 3) Serum Calcium-Phosphorus (Ca-P) product to below 55 mg²/dL² (4.4 mmol/L); 4) to avoid hypercalciuria; 5) to avoid hypercalcemia; and 6) to avoid renal (nephrocalcinosis/nephrolithiasis) and other extra skeletal calcifications [4]. For the treatment of hypoPT, calcium and activated Vitamin D replacement are used.
The most common oral Ca with the highest percentage of elemental Ca is calcium carbonate (CaCO3). It should be taken with meals and its absorption depends on the gastric acidity. Particular food can increase or decrease absorption and bioavailability of the mineral. CaCO3 can cause gastrointestinal side effects such as bloating or constipation [6]. Calcium citrate has greater absorption in the small intestine since it is not affected by gastric acid and can be taken with proton pump inhibitors. However, it is more expensive and requires greater number of tablets because of lower elemental Ca content. Activated 1α hydroxylated vitamin D analogs are also essential for Ca absorption, with most commonly used forms 1,25 dihydroxy vitamin D (calcitriol) and 1α calcidiol. The short half-life of calcitriol mandates twice daily administration. Recombinant PTH (1-84) is another option in cases in whom clinical targets are not maintained despite high doses of calcium and active vitamin D supplements [6–9]. Optimizing the biochemical and clinical parameters without causing short- and long-term complications remain a challenge for endocrinologists. It is known that quality of life is significantly affected in individuals with chronic hypoPT. There are no objective clinical tools to measure and quantify the symptom burden of the patients. Reduced quality of life is closely related with calcium fluctuation. Compliance to that lifelong medical therapy is difficult in-patient terms. To our knowledge there is no data in the literature about the patient compliance to medical treatment in patients with post-surgical chronic hypoPT. In this study our aim was to demonstrate the motivation and acknowledgement status of patients about calcium and calcitriol treatment and reveal the factors that can affect compliance. This study is the first one in the literature performed in hypoPT patients.

**Material And Method**

The patients who were admitted to our endocrinology outpatient clinics between May 2017 and January 2018 with the diagnosis of persistent postsurgical hypoPT were enrolled in this study. This study was designed as a single center prospective study and it was approved by the local ethics committee. Persistent or chronic hypoPT was defined as hypoparathyroidism lasting at least one year after operation. After recording medical history and making physical examination, the patients were requested to fill the form of “Medication Adherence Questionnaire“ (MAQ) [11, 12]. The endocrinologist accompanied each patient while filling the form and explained each question one by one. MAQ was previously translated in our language by a professional then confirmed and validated by three separate researchers [13]. This questionnaire includes six questions. The first question asks if the patient forgets to take the medication. Second question asks if the patient takes the medication on time. Third question asks if the patient skips the medication when he/she feels well. Forth question asks if the patient experiences adverse effects which he/she relates with the medication leading to incompliance. Fifth question asks if the patient knows the benefits of the medication and lastly sixth question asks if the patient forgets to get prescriptions for the medication on time. The answer is either yes or no. The patients are scored regarding the response."Yes" to question 2 and five is scored as 1 and "No “is scored as 0 point. Answer “Yes” to the remaining questions is scored as 0 whereas “No” is scored as 1 point. The first, second and sixth questions reflect the motivation status of the patients. If the score is above 1 to those mentioned questions, it is interpreted as “patient is motivated”. If the total score is less than one, it
is interpreted as “the patient is not motivated to the treatment”. The third, forth and sixth questions reflect
the knowledge about the medication that is received. If the total score of the responses to those
questions are above 1, that means patient has adequate knowledge whereas score below 1 means the
patient does not have adequate knowledge.

The patients were also questioned whether or not they experience drug related anxiety (calcium
supplements and active vitamin D). It was also asked if they ever pause using the medications and
frequency was questioned if the answer was “yes”.

The demographic data of the patients such as age, sex, education level, marital status, occupation and
comorbid chronic conditions, durance of hypoparathyroidism, presence of thyroid malignancy, presence
of neuropsychiatric disturbance, renal stone, concomitant thyroid malignancy, presence of disease related
hospitalization or emergency admittance were recorded.

Statistical Analysis

Statistical analyses were performed using SPSS version 17 (SPSS Inc. Chicago, IL, USA). Continuous
variables were presented as USA). Normality of distribution was tested by Saphira Wilkins test.
Descriptive analysis was presented as mean ±SD or median (min-max) where appropriate. Categorical
variables were demonstrated as percentage and numbers. The Mann Whitney U Test was used to
compare differences between two independent groups for the continuous variables whereas Kruskal
Wallis was used to compare more than two groups. Fishers exact test or binominal test was used to
determine if there were nonrandom associations between two categorical variables. Motivation and
knowledge scores and drug compliance were compared with Wilcoxon signed rank test. The correlation
of disease durance with knowledge and motivation scores were assessed by Spearman correlation test. P
<0.005 was accepted as statistically significant

Results

A total of 64 patients were enrolled. Twelve patients were male, fifty-two were female and the mean age
was 48.6± 11.6 years. Median disease durance defined as the time interval between disease diagnosis
and the last clinical visit was 60 months (min -max ;12-295 months). Mean elemental calcium
replacement dosage was 1388± 897.92 mg whereas mean calcitriol dosage was 0.61± 0.39 µg.
Emergency admittance history due to hypocalcemia symptoms was present in %26.6 of the patients. The
demographic data of the patients was shown on Table1. Fifty nine percent (n=38) of the patients reported
anxiety due to possible side effects of calcium supplements. The percentage of patients who take time
off the calcium treatment due to anxiety was %15.6 (n=10). The percentage of patients who experience
anxiety due to active vitamin D side effects was 13.3% (n=8). Nobody gave a break to active vitamin D
because of the side effect anxiety (Table 2). Education level did not affect the drug compliance (Table 3).
Regarding to the histopathology reports, the patients with a concomitant thyroid malignancy had similar
motivation and information scores for oral calcium and calcitriol compared to ones without concomitant
thyroid malignancy (Table 4). The median motivation score for calcium treatment was lower than calcitriol treatment \((p<0.001)\) whereas distribution of patients in two different motivation groups were similar for calcium and calcitriol treatments. There was no difference regarding the drug acknowledgement scores /degrees for calcium and calcitriol \((p=0.097\) and \(0.007,\) respectively). The rate of drug incompliance was higher for calcium than it is for calcitriol \((p=0.002)\) (Table 5). There was no significant correlation between emergency admittance and calcium/ calcitriol motivation scores and acknowledgement scores (Supp Table 1).

**Table 1. Demographic and clinical data of the patients \((n=64)\)**
| Age years (mean) | 48.6±11.6 |
|------------------|-----------|
| **Sex**          |           |
| *Male*           | 12 (18.8%)|
| *Female*         | 52 (81.2%)|
| **Education level** |        |
| *Primary*        | 35 (%54.7)|
| *Secondary*      | 7 (%10.9)|
| *High*           | 9 (%14.1)|
| *University*     | 13 (%20.3)|
| **Marital status** |      |
| *Married*        | 53 (82.8)|
| *Single*         | 6 (%9.4)|
| *Widow*          | 5 (%7.8)|
| **Occupation**   |           |
| *Actively working* | 13 (20.3%)|
| *Not working*    | 41 (64.1%)|
| *Retired*        | 10 (15.6%)|
| **HypoPT Duration (months)** | 60 (7-395%) |
| **DM**           | 4 (6.3%) |
| **HT**           | 16 (25.0%)|
| **Neuropsychiatric disease** | 13 (20.3%) |
| **Renal Stone**  | 13 (20.3%)|
| **Malignancy**   | 39 (60.9%)|
| **Hospitalization due to hypoPT** | 1 (1.6%) |
| **Emergency admittance** | 17 (26.6%) |

DM: Diabetes Mellitus, HT: Hypertension, hypoPT: Hypoparathyroidism
Table 2  
Descriptives of drug anxiety and compliance status (n=64)

| Calcium side effect anxiety |  |
|-----------------------------|--|
| Present                     | 38 (59.4%) |
| Not present                 | 26 (40.6%) |

| Giving off the drug due to anxiety |  |
|-----------------------------------|--|
| Yes                               | 10 (15.6%) |
| No                                | 54 (84.4%) |

| Frequency of giving off Calcium tablets |  |
|----------------------------------------|--|
| Always                                 | 3 (4.7%) |
| Frequently                             | 3 (4.7%) |
| Sometimes                              | 3 (4.7%) |
| Rarely                                 | 25 (39.1%) |
| Never                                  | 30 (46.9%) |

| Active vitamin D side effect anxiety |  |
|-------------------------------------|--|
| Present                             | 8 (13.3%) |
| Not present                         | 52 (86.7%) |

| Frequency of giving off active vitamin D tablets |  |
|--------------------------------------------------|--|
| Frequently                                       | 1 (1.5%) |
| Sometimes                                        | 16 (26.7%) |
| Very rare                                        | 43 (71.7%) |

| Using the drugs lower than the recommended dosage |  |
|--------------------------------------------------|--|
| Yes                                               | 21 (32.8%) |
| No                                                | 43 (67.2%) |
Table 3
Ca and active vitamin D treatment motivation to and knowledge scores regarding to education levels of the patients (n=64)

|                          | Primary | Secondary | High school | University | p-value |
|--------------------------|---------|-----------|-------------|------------|---------|
| **Ca motivation score**  | 2 (0-3) | 3 (1-3)   | 3 (2-3)     | 2 (0-3)    | 0.198†  |
| **Ca motivation level**  |         |           |             |            | 0.151‡  |
| Low                      | 10 (30.3%) | 2 (28.6%) | 0 (0.0%)    | 4 (30.8%)  |         |
| High                     | 23 (69.7%) | 5 (71.4%) | 8 (100.0%)  | 9 (69.2%)  |         |
| **Ca knowledge score**   | 2 (0-3) | 2 (1-3)   | 2 (2-3)     | 2 (1-3)    | 0.314†  |
| **Ca knowledge level**   |         |           |             |            | 0.178‡  |
| Low                      | 9 (27.3%) | 1 (14.3%) | 0 (0.0%)    | 2 (15.4%)  |         |
| High                     | 24 (72.7%) | 6 (85.7%) | 8 (100.0%)  | 11 (84.6%) |         |
| **Active Vitamin D**     |         |           |             |            | 0.109†  |
| motivation score         | 3 (1-3) | 3 (2-3)   | 3 (2-3)     | 3 (2-3)    |         |
| **Active Vitamin D**     |         |           |             |            | 0.056‡  |
| motivation level         |         |           |             |            |         |
| Low                      | 8 (24.2%) | 0 (0.0%)  | 0 (0.0%)    | 0 (0.0%)   |         |
| High                     | 25 (75.8%) | 7 (100.0%) | 9 (100.0%) | 11 (100.0%) |         |
| **Active Vitamin D**     |         |           |             |            | 0.130†  |
| knowledge score          | 2 (0-3) | 2 (2-3)   | 2 (2-3)     | 2 (2-3)    |         |
| **Active Vitamin D**     |         |           |             |            | 0.171‡  |
| knowledge level          |         |           |             |            |         |
| Low                      | 4 (12.1%) | 0 (0.0%)  | 0 (0.0%)    | 0 (0.0%)   |         |
| High                     | 29 (87.9%) | 7 (100.0%) | 9 (100.0%) | 11 (100.0%) |         |

† Wilcoxon sign test, ‡ McNemar test, Ca: Calcium
|                          | Malignancy (-) | Malignancy (+) | p-value |
|--------------------------|----------------|----------------|---------|
| **Ca motivation score**  | 2 (0-3)        | 2 (0-3)        | 0.802†  |
| Ca motivation level      |                |                |         |
| *low*                    | 6 (25.0%)      | 10 (27.0%)     | >0.999‡ |
| *High*                   | 18 (75.0%)     | 27 (73.0%)     |         |
| **Ca knowledge score**   | 0 (0-3)        | 2 (0-3)        | 0.597†  |
| Ca knowledge level       |                |                |         |
| *Low*                    | 5 (20.8%)      | 7 (18.9%)      | >0.999¶ |
| *High*                   | 19 (79.2%)     | 30 (81.1%)     |         |
| **Active Vitamin D motivation score** | 3 (1-3) | 3 (1-3) | 0.133† |
| Active Vitamin D motivation level |            |                |         |
| *Low*                    | 2 (8.7%)       | 6 (16.2%)      | 0.698¶ |
| *High*                   | 21 (91.3%)     | 31 (83.8%)     |         |
| **Active Vitamin D knowledge score** | 2 (1-3) | 2 (0-3) | 0.955† |
| Active Vitamin D knowledge level |            |                |         |
| *Low*                    | 2 (8.7%)       | 2 (5.4%)       | 0.634¶ |
| *High*                   | 21 (91.3%)     | 35 (94.6%)     |         |

† Wilcoxon sign test, ‡ McNemar test, Ca: Calcium
Table 5
Comparison of motivation/acknowledgement scores of Ca and Vitamin D

|                      | CaCO3       | Vitamin D   | p-value     |
|----------------------|-------------|-------------|-------------|
| Motivation score     | 2 (0-3)     | 3 (1-3)     | <0.001†     |
| Motivation level     |             |             | 0.070‡      |
| Low                  | 14 (24.6%)  | 8 (14.0%)   |             |
| High                 | 43 (75.4%)  | 49 (86.0%)  |             |
| Knowledge score      | 2 (0-3)     | 2 (0-3)     | 0.097†      |
| Knowledge level      |             |             | 0.070‡      |
| Low                  | 10 (17.5%)  | 4 (7.0%)    |             |
| High                 | 47 (82.5%)  | 53 (93.0%)  |             |
| Incompliance to the drug |         |             | 0.002†      |
| Always               | 3 (%5.0)    | -           |             |
| Frequently           | 2 (%3.3)    | 1 (%1.7)    |             |
| Sometimes            | 3 (%5.0)    | -           |             |
| Rarely               | 23 (%38.3)  | 16 (%26.7)  |             |
| Never                | 29 (%48.3)  | 43 (%71.7)  |             |

† Wilcoxon sign test, ‡ McNemar test, Ca: Calcium,

The most common worry about calcium usage was nephrotoxicity that was present in 55.2% (n=21) of the patients. Anxiety about the gastrointestinal side effects of calcium was present in 26.3% (n=11). The most common worry about calcitriol reported by the patients were kidney damage and polyuria (50%). One third (33%) of the patients were taking oral calcium and calcitriol less than the prescribed and recommended dose whereas 67% were taking them as advised. The calcium motivation score was reversely correlated with disease duration (r= -0.256 and p=0.046). the 22% (n=14) reported that calcium prepareate had a nice taste whereas 53% (n=43) reported a bitter taste. Sixteen patients (25%) reported a neutral taste.

Discussion

Evaluation of adherence to oral medications in permanent hypoPT patients is extremely important for preventing hypocalcemia related symptoms without causing side effects such as nephrocalcinosis. There is no previous study in the literature evaluating the drug compliance and related factors in patients with
hypoPT. The quality of life evaluated with “Short Form 36 and Hospital Anxiety and Depression scale” was reported to be lower in hypoPT patients due to lifelong treatment burden of medications, need for hospitalizations or frequent visits and fluctuating serum Ca levels [14]. Post-surgical hypoPT was also found to be correlated with lower quality of life scores compared with other hypoPT subtypes in that study. Despite calcium and active vitamin D replacement, some patients may still experience physical and emotional symptoms regardless of the serum Ca level since parathyroid hormone receptors are distributed in central nervous system and muscle tissues [15].

In this study, the emergency admittance because of hypoPT or its complications was found 26.6% of the patients. In a previous study 42 of 120 patients (33%) had at least one hypoPT related emergency admittance after diagnosis [16]. The lower rate of disease related emergencies in our patient group may be related to younger age compared with the mentioned study. Most common hypo PT symptom was muscle weakness in the previous studies. Sikjaer et al reported that muscle functions are affected more severely in patients with concomitant hypothyroidism and hypo PT compared to hypo PT alone and control groups [17].

In this study prevalence of psychiatric diseases (depression and anxiety disorders) in hypo PT patients was 20.3%. Like our study, previous reports suggested more prevalent anxiety, phobia and depression compared to control group despite keeping the calcium levels in the normal range [18, 19]. In a cohort of patients in Denmark, hospitalization due to depression, bipolar disorder and infections were higher in hypoPT patients compared to controls [20]. In our study almost 60% of patients had worries about calcium carbonate side effects and 13.3% had worries about calcitriol adverse effects. The most common source of anxiety was giving harm to kidneys or gastrointestinal disturbances such as bloating and constipation. Twenty percent of our study group had history of nephrolithiasis.

To our knowledge there is scarce indeed no study in the literature evaluating drug compliance in post-surgical hypo PT patients. Compliance to calcium and vitamin D replacement was previously studied in patients with osteoporosis [21, 22]. But those patient populations are different from ours regarding the advanced age and significant female predominance. In a previous study, using Morisky-Green test, osteoporosis patients detected to have poor compliance to calcium and vitamin D. The major determinants of drug incompliance were reported to be memory problems and high costs [23]. In our patient group all patients had social health security covering the costs so the major reason of incompliance was thought to be side effects. In a study by Branco et al only two of every ten patients who received a prescription for Ca and vitamin D persisted and complied properly with the treatment 1 year after beginning it [24]. The possible explanations for incompliance included the presence of psychiatric disorders, cognitive impairment, provider-patient relationship, complexity of treatment, and barriers to care. Physician’s attitude was reported to be an important factor to increase the awareness of the patients about the benefits of the treatment and risks of giving drug holidays. In a previous study it was shown that specific activities aimed to strengthen motivation of the patients as scheduling periodic follow-up visits every 6 months seem ed to increase the adherence to calcium and vitamin D
supplementation after only 6 months [25]. In that study drug adherence was correlated with age as the youngers had more compliance in contrast to our study result.

In our study the motivation and knowledge about the drugs and adherence level was higher compared to previous ones conducted in different patient populations. That might be due to the highly selected group of individuals in this study who admitted to a tertiary endocrine center with postoperative hypoparathyroidism. The major determinant of incompliance was disease duration which can be explained by patient exhaustion. We cant draw direct conclusions from the previous reports since they were conducted in osteoporotic patients in whom drug adherence is not as vital as in hypo PT. Motivation score is lower for calcium than calcitriol in this study possibly because of the larger and tablet sizes and the bitter taste.

Our study is the first one evaluating drug compliance and factors effecting it in post-surgical hypo PT. The limitation is the small number of patients and lack of laboratory data reflecting the disease control status.

In conclusion, one third of patients in our study lack motivation to use calcium whereas half of the patients’ experiences anxiety about drug related side effects. Drug motivation further decrease as the disease duration increase. This is a preliminary study showing that vital calcium and active vitamin D intake may be interrupted due to side effect anxiety and motivation can be increased by frequent visits and acknowledging the patient about the deleterious effects of drug withdrawal.

Declarations

Funding No funding was received for conducting this study.

Conflict of interest Muhammet Cuneyt Bilginer, Cevdet Aydin, Burcak Polat, Sevgul Faki, Oya Topaloglu, Reyhan Ersoy and Bekir Cakir declare that they have no conflict of interest. The authors declare no competing financial interests.

Ethical approval The study protocol was approved Ankara Ataturk Education and Research Hospital and complied with the principles of the Declaration of Helsinki.

Consent for publication Patients signed informed consent regarding publishing their data.

References

1. Bilezikian JP, Khan A, Potts JT Jr (2009). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Third International Workshop. J Clin Endocrinol Metab. 94:335–339. https://doi.org/10.1210/jc.2008-1763

2. Powers J, Joy K, Ruscio A, Lagast H (2013). Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. Dec;28(12):2570-6.
3. Marx SJ. Hyperparathyroid and hypoparathyroid disorders (2000). New Engl J Med. 343:1863–1875. https://doi.org/10.1056/NEJM200012213432508

4. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr (2016). Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. Jun;101(6):2273-83. https://doi.org/10.1210/jc.2015-3907

5. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM (2015). European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. Aug;173(2):G1-20. https://doi.org/10.1530/EJE-15-0628

6. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr (2016). Management of Hypoparathyroidism: Present and Future. J Clin Endocrinol Metab. Jun;101(6):2313-24. https://doi.org/10.1210/jc.2015-3910

7. Lakatos P, Bajnok L, Lagast H, Valkusz Z (2016). AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM. Endocr Pract. May;22(5):523-32. https://doi.org/10.4158/EP15936.OR

8. Winer KK, Yanovski JA, Cutler GB, Jr (1996). Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 276:631–636.

9. Mitchell DB, Regan S, Cooley MR, Lauter KB, Vrla Mc, Becker CB, Burnett-Bowie SAM, Mannstadt M (2012). Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 97:4507-4514. https://doi.org/10.1210/jc.2012-1808

10. Case Management Society of America (CMSA). CMAG: Case management adherence guidelines. Guidelines from the Case Management Society of America for improving patient adherence to medication therapies. Version 2.0. June 2006. Available at: http://www.cmsa.org/portals/0/pdf/pdf. Accessed Dec 16, 2016.

11. Morisky DE, Green LW, Levine DM (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 24(1):67-74.

12. Son NE, Taskiran B, Yorulmaz G, Son O, Kokoglu B, Bilgin M, Bilge, U (2017). Relationship between the 6-item Morisky Medication Adherence Scale (MMAS-6) score and glycemic control in a Turkish population with type 2 diabetes mellitus. Acta Medica Mediterranea. vol.33, no.6, 921-928.

13. Vural B, Teberru Acar Ö, Topsever P, Filiz TM (2012). Modifiye Morisky Ölçeğinin Türkçe geçerlilik güvenirilik çalışması. Turkish Family Physician. 3(4):17-20

14. Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svardberg J, Husebye ES (2016). Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. Aug;101(8):3045-53. https://doi.org/10.1210/jc.2016-1477

15. Büttner M, Musholt TJ, Singer S (2017). Quality of life in patients with hypoparathyroidism receiving Standard treatment: a systematic review. Endocrine. Oct;58(1):14-20.
https://doi.org/10.1007/s12020-017-1377-3

16. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012). Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. Dec;97(12):4507-14. https://doi.org/10.1210/jc.2012-1808

17. Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, Rejnmark L (2016). Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism. J Bone Miner Res. Jul;31(7):1440-8. https://doi.org/10.1002/jbmr.2812

18. Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002). Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. Feb;146(2):215-22. https://doi.org/10.1530/eje.0.1460215

19. Khan AA, Koch C, Van Uum SHM, et al (2018). Standards of Care for Hypoparathyroidism in Adults Eur J Endocrinol. 180(3):P1–P22. https://doi.org/10.1530/EJE-18-0609

20. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014). Postsurgical hypoparathyroidism—risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. Nov;29(11):2504-10. https://doi.org/10.1002/jbmr.2273

21. Touskova T, Vytrisalova M, Palicka V, Hendrychova T, Chen YT, Fuksa L (2016). Patterns of Non-adherence to Supplementation with Calcium and Vitamin D in Persistent Postmenopausal Women Are Similar at Start and 1 Year Later: A Qualitative Longitudinal Study. Front Pharmacol. 7:339. https://doi.org/10.3389/fphar.2016.00339

22. Marina Maksimovic, Vladimir Jurisic, Biljana Erdeljan, Dragana Dojcincovic (2017). The evaluation of the adherence to calcium, vitamin D and drugs for osteoporosis in patients with low bone mineral density. Srpski arhiv za celokupno lekarstvo. 145(00):41-41. https://doi.org/10.2298/SARH160524041M

23. Castelo-Branco C, Cortés X, Ferrer M; UNICAD study investigators (2010). Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric. Dec;13(6):578-84. https://doi.org/10.3109/13697130903452804

24. Conti F, Piscitelli P, Italiano G, Parma A, Caffetti MC, Giolli L, Di Tanna GL, Guazzini A, Brandi ML (2012). Adherence to Calcium and Vitamin D supplementations: results from the ADVICE Survey. Clin Cases Miner Bone Metab. Sep;9(3):157-60.

25. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007). Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. Dec;82(12):1493-501. https://doi.org/10.1016/S0025-6196(11)61093-8

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• HypoPTSupp1.docx